All Outputs (4)

Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure (2017)
Journal Article
Nikolaidou, T., Pellicori, P., Zhang, J., Kazmi, S., Goode, K. M., Cleland, J. G., & Clark, A. L. (2018). Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure. Clinical Research in Cardiology, 107(2), 108-119. https://doi.org/10.1007/s00392-017-1162-6

© 2017 The Author(s) Aims: To determine the prevalence, incidence, predictors, and prognostic implications of PR interval prolongation in patients referred with suspected heart failure. Methods and results: Consecutive patients referred with suspecte... Read More about Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure.

Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure (2017)
Journal Article
Fröhlich, H., Torres, L., Täger, T., Schellberg, D., Corletto, A., Kazmi, S., Goode, K., Grundtvig, M., Hole, T., Katus, H. A., Cleland, J. G. F., Atar, D., Clark, A. L., Agewall, S., & Frankenstein, L. (2017). Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology, 106(9), 711-721. https://doi.org/10.1007/s00392-017-1115-0

© 2017, Springer-Verlag Berlin Heidelberg. Aims: Beta-blockers are recommended for the treatment of chronic heart failure (CHF). However, it is disputed whether beta-blockers exert a class effect or whether there are differences in efficacy between a... Read More about Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.

Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure (2017)
Journal Article
Fröhlich, H., Raman, N., Täger, T., Schellberg, D., Goode, K. M., Kazmi, S., Grundtvig, M., Hole, T., Cleland, J. G., Katus, H. A., Agewall, S., Clark, A. L., Atar, D., & Frankenstein, L. (2017). Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. International journal of cardiology, 238, 97-104. https://doi.org/10.1016/j.ijcard.2017.03.028

© 2017 Elsevier B.V. Background In patients with chronic heart failure (CHF) increasing levels of total serum cholesterol are associated with improved survival – while statin usage is not. The impact of statin treatment on the “reverse epidemiology”... Read More about Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure.

What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? (2017)
Journal Article
Pellicori, P., Urbinati, A., Shah, P., MacNamara, A., Kazmi, S., Dierckx, R., …Clark, A. L. (2017). What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?. European journal of heart failure, 19(6), 768-778. https://doi.org/10.1002/ejhf.788

Aims The PARADIGM-HF trial showed that sacubitril–valsartan, an ARB–neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is uncertain what proportion of patients with HF would be eligible for sacubitril... Read More about What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?.